Gyre Therapeutics, Inc. (GYRE)
4.555
-1.86
(-28.94%)
USD |
NASDAQ |
Oct 30, 16:00
4.64
+0.08
(+1.87%)
After-Hours: 20:00
Gyre Therapeutics Enterprise Value : 468.60M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 468.60M |
| October 29, 2026 | 665.29M |
| October 28, 2026 | 737.39M |
| October 27, 2026 | 678.01M |
| October 26, 2026 | 629.24M |
| October 23, 2026 | 605.91M |
| October 22, 2026 | 606.97M |
| October 21, 2026 | 611.21M |
| October 20, 2026 | 639.84M |
| October 19, 2026 | 631.36M |
| October 16, 2026 | 630.30M |
| October 15, 2026 | 664.23M |
| October 14, 2026 | 671.65M |
| October 13, 2026 | 697.10M |
| October 12, 2026 | 713.54M |
| October 09, 2026 | 732.09M |
| October 08, 2026 | 702.40M |
| October 07, 2026 | 732.09M |
| October 06, 2026 | 736.33M |
| October 05, 2026 | 764.96M |
| October 02, 2026 | 739.51M |
| October 01, 2026 | 727.85M |
| September 30, 2026 | 762.84M |
| September 29, 2026 | 761.78M |
| September 28, 2026 | 779.81M |
| Date | Value |
|---|---|
| September 25, 2026 | 764.96M |
| September 24, 2026 | 762.84M |
| September 23, 2026 | 770.26M |
| September 22, 2026 | 779.81M |
| September 21, 2026 | 773.44M |
| September 18, 2026 | 786.17M |
| September 17, 2026 | 746.94M |
| September 16, 2026 | 696.04M |
| September 15, 2026 | 694.98M |
| September 14, 2026 | 694.98M |
| September 11, 2026 | 699.22M |
| September 10, 2026 | 700.28M |
| September 09, 2026 | 722.55M |
| September 08, 2026 | 745.88M |
| September 04, 2026 | 713.00M |
| September 03, 2026 | 668.47M |
| September 02, 2026 | 659.99M |
| September 01, 2026 | 671.65M |
| August 31, 2026 | 682.26M |
| August 28, 2026 | 684.38M |
| August 27, 2026 | 693.92M |
| August 26, 2026 | 690.74M |
| August 25, 2026 | 693.92M |
| August 24, 2026 | 668.47M |
| August 21, 2026 | 718.31M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cytokinetics, Inc. | 8.842B |
| Incyte Corp. | 20.74B |
| ACADIA Pharmaceuticals, Inc. | 2.662B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 267.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.27M |
| Revenue (Quarterly) | 29.10M |
| Total Expenses (Quarterly) | 39.71M |
| EPS Diluted (Quarterly) | -0.1159 |
| Gross Profit Margin (Quarterly) | 92.41% |
| Profit Margin (Quarterly) | -49.03% |
| Earnings Yield | -4.30% |
| Normalized Earnings Yield | -3.873 |